Physician profile
George Philip
NPI 1326284902
$4,844.02
in general payments reported to CMS, 2019-2025
25 companies · $601 in 2025
The $601 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $679 · 2021: $321 · 2022: $625 · 2023: $882 · 2024: $820 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,303.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,302.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $962.91 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $917.82 | 2019-2025 | Lifevest |
| Amgen INC. | $876.54 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $389.41 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $307.94 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $202.51 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $190.00 | 2019-2025 | Farxiga, Wainua |
| Biotronik INC. | $181.48 | 2019-2022 | |
| Esperion Therapeutics, INC. | $153.77 | 2020-2025 | Nexletol |
| E.R. Squibb & Sons, L.L.C. | $115.61 | 2019-2025 | Camzyos |
| Astellas Pharma US INC | $109.26 | 2019-2021 | |
| Irhythm Technologies, INC. | $87.14 | 2021-2024 | Zio Xt Patch, Zio Monitor |
| Merck Sharp & Dohme LLC | $72.15 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $46.85 | 2024-2025 | Wegovy |
| Regeneron Healthcare Solutions, INC. | $35.02 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $24.69 | 2023 | Opsumit |
| Alnylam Pharmaceuticals INC. | $22.64 | 2025 | Amvuttra |
| Medtronic, INC. | $22.39 | 2023 | Linq II |
| Bridgebio Pharma, INC. | $21.88 | 2025 | Attruby |
| Lexicon Pharmaceuticals, INC. | $20.33 | 2023 | Inpefa |
| Siemens Medical Solutions USA, INC. | $20.26 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.74 | 2024 | Jardiance |
| Preventice Services, LLC | $16.39 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $15.81 | 2019 | |
| Scpharmaceuticals INC. | $14.48 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Philip listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.